Gilead Sciences, Inc. (NASDAQ:GILD)

CAPS Rating: 4 out of 5

A biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.

Results 1 - 20 of 316 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar TMFJoeFriday (34.09) Submitted: 4/16/2014 5:54:15 PM : Outperform Start Price: $69.37 GILD Score: +0.63

Sovaldi revenue will be colossal, and the pushback against its pricing has bred market uncertainty on the stock, giving value investors an excellent window to buy.

Recs

0
Member Avatar samunitions (< 20) Submitted: 4/15/2014 8:33:28 PM : Outperform Start Price: $69.32 GILD Score: +0.48

The hepatitis C new cure is a game changer and massive new stream of revenue

Recs

0
Member Avatar SmartAce (99.82) Submitted: 4/14/2014 1:07:48 PM : Outperform Start Price: $68.36 GILD Score: +0.69

GILD trades at 10% and 12% free cash flow yield on 2015E and 2016E

Recs

0
Member Avatar IRA2014 (44.99) Submitted: 4/14/2014 11:47:25 AM : Outperform Start Price: $67.78 GILD Score: +1.56

S&P credit rating A-. 28 analysts say earnings growth will be about 31%. With the recent bio bubble bursting some quality names have taken hits. I think GILD is one of those names. I've watched it run for a while now and couldn't pull the trigger.

I won't pretend to know how far this guy falls before it puts in a bottom. To be honest I don't care. Don't get me wrong I'd love say it's uphill from here but I know enough to know that I don't know. (that make sense?) I think it's a great value right now though on a great company. I bought about 2/3 of what I'd like to have. Maybe I should have went less. We'll see.

I like it. I'm in. I think it could pop 30% from here in the next 3-6 months. Wishing myself luck,

Recs

0
Member Avatar racoveanul (83.65) Submitted: 4/12/2014 3:08:24 PM : Outperform Start Price: $67.79 GILD Score: +1.37

GILD has an A for financial health and a PEG less than 1 on Morningstar, so it's one of my long picks.

Recs

0
Member Avatar usubanas (99.53) Submitted: 4/8/2014 11:38:13 AM : Underperform Start Price: $70.68 GILD Score: +1.82

Pressure on it's high-cost HCV drug is only going to get worse. Plus their HIV franchise will also face challenges.

Recs

0
Member Avatar kahunacfa (67.92) Submitted: 4/7/2014 3:07:43 PM : Outperform Start Price: $71.83 GILD Score: -3.45

The company has one of the few effective HIV agents. HIV infections are still a huge world-wide public health problem, especially in Africa, but also world-wide.

Kahuna, CFA
UWASAP.org

Recs

0
Member Avatar Mikeru22 (37.12) Submitted: 4/2/2014 10:06:03 AM : Outperform Start Price: $74.69 GILD Score: -5.24

Strong growth potential.

Recs

0
Member Avatar toyotamoney (23.51) Submitted: 3/28/2014 6:24:50 PM : Outperform Start Price: $69.17 GILD Score: +1.34

Undervalued compared to peers

Recs

0
Member Avatar TSIF (99.96) Submitted: 3/28/2014 6:02:26 PM : Outperform Start Price: $67.99 GILD Score: +2.36

Returning to the scene of the "crime".

The jury is out on whether the Congressional inquiry that questioned the pricing of its hepatitis C drug, Sovaldi. caused, enhanced, or had nothing to do with the severe, broad area Biopharm pullback. You can see more of my thoughts on this on my March blogs.

At this point the 20% pullback has nearly every analyst screaming what a buy Gilead is. Personally, the Biopharm correction appears to me to have already been in "play" as institutions were rebalancing.

I can not give an educated reply on if $84,000 is too expensive for a drug that has better results, and reduces other complication is too much to pay. Personally, it's not too much by a long shot in comparison to other drugs, and I support the cost/risk that goes into generating the few successful drugs. After which there is a short time until Generics can take over and something new is needed.

I believe ZERO, other than maybe some offers to further help low income people or slightly smaller Medicaid charges will come of the "inquiry"....

The overall Hep-C program is gaining market share, and Gilead has other drugs, especially in the area of HIV that are profitable.

Yes, Biopharms have "rather high" P/E's and metrics. A 117B (after the haircut) Market cap and a 37P/E sounds expensive, but margins are high and revenue increasing.

IF the biopharms continue to correct, Gilead will drop more. The trend is still downward as I write this. I'll put my stake in the ground here for observation...risk reward is looking interesting. If Gilead starts to rise, especially if it's the markets shrugging off the pricing, ",most' of the other bios should rise as well.

Recs

0
Member Avatar bobg304 (43.77) Submitted: 3/28/2014 1:03:36 PM : Outperform Start Price: $69.27 GILD Score: +0.80

JUST TO CHEAP...

Recs

0
Member Avatar OklaBoston (68.16) Submitted: 3/9/2014 8:29:42 PM : Underperform Start Price: $75.96 GILD Score: +8.28

All Stars have ended many green thumbs here the last few months.

Good Q/Q numbers but debt just too high for my taste and valuations look inflated.

This will need more good quarters to stay above $60, IMO.

Recs

0
Member Avatar Chemdawg (81.29) Submitted: 3/7/2014 2:10:29 AM : Outperform Start Price: $81.21 GILD Score: -12.49

tailwinds behind the entire sector

Recs

0
Member Avatar TerryFool (21.60) Submitted: 2/25/2014 9:43:06 AM : Outperform Start Price: $79.90 GILD Score: -11.44

GILD BP 78. TP 98 REV 1yr 15% EPS 1yr 18%

Recs

0
Member Avatar lepera347 (66.31) Submitted: 2/24/2014 3:34:31 PM : Outperform Start Price: $83.65 GILD Score: -16.88

Best in the sector

Recs

0
Member Avatar ZenRiDr (< 20) Submitted: 2/7/2014 6:45:43 PM : Outperform Start Price: $79.34 GILD Score: -15.49

Fantastic pipeline of drugs.

Recs

0
Member Avatar lemny (46.39) Submitted: 2/5/2014 9:45:47 AM : Outperform Start Price: $79.00 GILD Score: -18.10

Hep C drug is big

Recs

0
Member Avatar RoboSmart (< 20) Submitted: 2/1/2014 2:27:30 PM : Outperform Start Price: $81.77 GILD Score: -19.14

Their drug primary recommendation for treatment of Hep C with or without Interferon

Recs

0
Member Avatar macpsu (< 20) Submitted: 1/29/2014 8:59:02 AM : Outperform Start Price: $80.01 GILD Score: -17.48



Recs

0
Member Avatar rule72 (35.76) Submitted: 1/25/2014 1:01:03 AM : Outperform Start Price: $80.76 GILD Score: -17.42

It has one of the best HIV drug but does has resitant from the cost of the drug. insurance companies, oversea countries, adovacates to lower the price of the drug. Plus another drug company is now has a lower cost drug.

Featured Broker Partners


Advertisement